Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com
A11931 | Pages: NA | Charts: NA | Tables: NA |
The human epidermal growth factor receptor 2 (HER2) is used to control the protein on the cell surface that helps the cell to grow. It belongs to the family epidermal growth factor receptors. It is a trans-membrane tyrosine kinase receptor. The changes in HER2 result in the expansion of the tumor. If there are more than two cells of the HER2 gene, than it results in excessive amount of HER2 protein being made, and it is called overexpression of HER2. HER2 expression is detected on cell membranes of epithelial cells in the gastrointestinal tract, skin, breast, urinary tract, placenta, skeleton muscle cell, and on the heart. In fatal tissue, HER2 expression is mostly higher than normal adult tissue .HER2 breast cancer is one of the aggressive types of breast cancer caused due to over-expression of the HER2 protein.
COVID-19 Impact Analysis
COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
In the early phase of COVID-19 pandemic, there was no availability of specific diagnostic tests to detect the disease in patients. Alternative diagnostic tests were used initially but were not much effective. This unavailability of specific COVID-19 diagnostic tests presented lucrative opportunities for diagnostic manufacturers to introduce their COVID-19 diagnostic kits. Many leading players as well as some start-ups from various countries utilized this opportunity and introduced COVID-19 diagnostics kits into local as well as global market. These players achieved edge over other diagnostics players capitalizing the opportunity from demand for COVID-19 diagnostic tests, which, in turn, helps them in maintaining their revenues in such a crisis.
Owing to such factors, COVID 19 is expected to have a significant impact on the market HER2 antibodies market.
Top Impacting Factors
Market Trends
New Product Launches to Flourish the Market
In March 2021, MacroGenics launched MARGENZA for patients with pretreated metastatic HER2-positive breast cancer. MARGENZA is approved, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.
In May 2020, Daiichi Sankyo launched ENHERTU in Japan for patients with HER2 positive unresectable or metastatic breast cancer.
In December 2019, the Food and Drug Administration granted accelerated approval to for the treatment of adults with unrespectable (unable to be removed with surgery) or metastatic (when cancer cells spread to other parts of the body) &HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting
Surge in Usage in Breast Cancer Treatment
Increase in prevalence of breast cancer and rise in demand for targeted therapies contribute toward the growth of the market. In addition, surge in healthcare expenditure and collaborations & partnerships between key players to facilitate development of HER2 antibodies are some factors, which augment the market growth for HER2 antibodies.
Key Benefits of the Report
Questions Answered in the HER2 Antibodies Market Report
Key Market Segments
Key Market Players